# Identification of Key Sequence Motifs Essential for the Recognition of m6A Modification in RNA

## TL;DR

This study identifies key RNA sequence motifs crucial for recognizing m6A modifications, which are linked to various diseases and could improve cancer therapies.

## Contribution

The study identifies a peptide motif (m1p1) and its role in m6A recognition, revealing a potential mechanism for reader proteins.

## Key findings

- Phage display identified a peptide motif (m1p1) that recognizes m6A in DRACH sequences.
- The hnRNP A1 RRM domain sequence is crucial for binding m6A-modified RNAs.
- Understanding m6A recognition could lead to improved theranostic strategies for cancer.

## Abstract

N6-methyladenosine (m6A) constitutes the most prevalent nucleotide modification within eukaryotic messenger RNA (mRNA). Variations in m6A levels are associated with numerous human diseases and health conditions, including various forms of cancer, diabetes, neurological disorders, male infertility, and obesity. Nevertheless, the molecular mechanisms underpinning the recognition of m6A by different ‘reader’ proteins remain incompletely elucidated. In this study, we used phage display to identify key sequence features that methyl readers recognize in m6A. This study shows that m6A modifications affect the mRNA interactome. A peptide motif recognizing m6A in DRACH sequences suggests a common recognition mechanism, though proteins may use different methods to detect m6A in less accessible areas. The sequence of the hnRNP A1 RRM domain that aligns with the newly discovered m6A-binding peptide, m1p1, is crucial for the binding of m6A-modified RNAs, indicating a strong link between the m1p1 sequence and m6A recognition, which is key for recognizing m6A-modified, unstructured RNAs. Gaining a comprehensive understanding of the evolutionary influence of m6A on its reader proteins may facilitate the identification of additional m6A readers. These signature peptides could enhance theranostic approaches across cancers, enabling more targeted therapies.